Allergan plc Company Profile (NYSE:ACT)

About Allergan plc

Allergan plc logoActavis, Inc. formerly Watson Pharmaceuticals, Inc., is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: ACT
  • CUSIP: 00507K10
Key Metrics:
  • Previous Close: $299.00
  • 50 Day Moving Average: $297
  • 200 Day Moving Average: $285
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.24
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Allergan plc:

Analyst Ratings

Consensus Ratings for Allergan plc (NYSE:ACT) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $270.00 (9.70% downside)

Analysts' Ratings History for Allergan plc (NYSE:ACT)
DateFirmActionRatingPrice TargetDetails
3/28/2016Leerink SwannBoost Price TargetOutperform$180.00 -> $215.00View Rating Details
11/2/2015SusquehannaBoost Price TargetPositive$290.00 -> $325.00View Rating Details
6/4/2015Bank of America Corp.Set Price TargetBuy$350.00View Rating Details
6/3/2015Raymond James Financial Inc.Initiated CoverageOutperform$344.00View Rating Details
5/29/2015Deutsche Bank AGBoost Price TargetBuy$336.00 -> $343.00View Rating Details
5/29/2015Canaccord GenuityReiterated RatingBuy$352.00View Rating Details
5/28/2015Citigroup Inc.Initiated CoverageFocus List -> Focus List$360.00View Rating Details
5/11/2015GuggenheimSet Price TargetBuy$345.00 -> $355.00View Rating Details
5/8/2015Barclays PLCSet Price TargetHold$300.00View Rating Details
5/8/2015MizuhoInitiated CoverageBuy$358.00View Rating Details
4/8/2015Royal Bank Of CanadaReiterated RatingPositive$361.00View Rating Details
3/24/2015Sterne Agee CRTReiterated RatingBuy$315.00 -> $340.00View Rating Details
3/18/2015BMO Capital MarketsBoost Price TargetBuy$286.00 -> $373.00View Rating Details
3/17/2015Goldman Sachs Group Inc.Initiated CoverageBuy$365.00View Rating Details
3/11/2015JPMorgan Chase & Co.Initiated CoverageOverweight$310.00 -> $375.00View Rating Details
3/6/2015Edward JonesInitiated CoverageBuyView Rating Details
2/25/2015Sanford C. BernsteinBoost Price TargetOutperform$315.00 -> $350.00View Rating Details
2/20/2015ArgusBoost Price TargetBuy$310.00 -> $340.00View Rating Details
2/19/2015CRT CapitalSet Price TargetBuy$288.00 -> $315.00View Rating Details
12/4/2014Morgan StanleyBoost Price TargetOverweight$266.00 -> $315.00View Rating Details
9/4/2014Evercore ISIInitiated CoverageBuyView Rating Details
(Data available from 8/29/2014 forward)


Earnings History for Allergan plc (NYSE:ACT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan plc (NYSE:ACT)
Current Year EPS Consensus Estimate: $18 EPS
Next Year EPS Consensus Estimate: $21 EPS


Dividend History for Allergan plc (NYSE:ACT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Allergan plc (NYSE:ACT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.00View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.00View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.00View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.64View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.00View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.01View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.00View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.00View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.00View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.00View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.28View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Allergan plc (NYSE:ACT)
DateHeadline logoFive Healthcare Stocks Hedge Funds Like (NYSE:ACT) - August 29 at 3:47 PM
News IconHorizon Pharma sues Actavis, Lupin for Paragraph IV certifications on generic Pennsaid - (NYSE:ACT) - August 29 at 8:03 AM logoAllergan: An Undervalued Powerhouse (NYSE:ACT) - August 28 at 3:16 PM logoBillionaire John Paulson’s Favorite Healthcare Stocks Include The Latest Industry Punching Bag, Mylan (NYSE:ACT) - August 27 at 8:04 AM logoU.S. Stocks Fall as Drugmaker Selloff Ends Lull Before Yellen - Bloomberg (NYSE:ACT) - August 26 at 3:17 PM
News IconTeva Confirms PTABs Decisions on Two Patents in IPR Challenge to COPAXONE 40 mg (NYSE:ACT) - August 25 at 8:45 PM logo10 Stocks George Soros Is Buying in 2016 (NYSE:ACT) - August 25 at 3:19 PM logoSpecialty Pharma: Never Mind the Pricing Controversy, Fundamentals Will Win Out (NYSE:ACT) - August 25 at 3:19 PM logoTeva Confirms PTAB's Decisions on Two Patents in IPR Challenge to COPAXONE® 40 mg - Yahoo Finance (NYSE:ACT) - August 25 at 8:04 AM logoForm 487 Advisors Disciplined - (NYSE:ACT) - August 24 at 3:18 PM logoTeva Canada Innovation Announces Approval of Three-Times-a-Week COPAXONE 40mg/mL by Health Canada (NYSE:ACT) - August 23 at 9:23 AM
News IconAllergy Treatment Market Revenue, Opportunity, Forecast and Value Chain 2016-2026 (NYSE:ACT) - August 22 at 8:29 PM logoTeva Pharmaceutical: A Successful Bond Financing Program in 2016 (NYSE:ACT) - August 22 at 3:21 PM logoCarl Icahn Buys Allergan (NYSE:ACT) - August 22 at 3:21 PM
News IconRecent Developments Indicate Minimal Invasive Treatment More Acceptable to Patients (NYSE:ACT) - August 21 at 8:04 AM logoEuropean Commission Grants Marketing Authorization for Teva's CINQAERO® (reslizumab) - Business Wire (press release) (NYSE:ACT) - August 18 at 3:28 PM logoAllergan to Present at 2016 Wells Fargo Healthcare Conference - PR Newswire (press release) (NYSE:ACT) - August 18 at 3:28 PM
News IconPanel selects Pa. federal court for MDL against generic drug makers (NYSE:ACT) - August 18 at 11:41 AM
News IconFree Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) (NYSE:ACT) - August 18 at 11:41 AM logoAllergan to Present at 2016 Wells Fargo Healthcare Conference (NYSE:ACT) - August 18 at 11:41 AM
News IconPanel selects Pa. federal court for MDL against generic drug makers - Legal News Line (NYSE:ACT) - August 17 at 3:19 PM logoBillionaire Money Managers Sold off This Stock in the 2nd Quarter (NYSE:ACT) - August 17 at 3:19 PM logoBig Changes At The Top of Passport Capital’s Portfolio As Yahoo (YHOO) Takes Top Spot (NYSE:ACT) - August 17 at 3:19 PM logo13F 2Q Wrap: Big Bets on Allergan; Buffett Buys Apple; Soros Sells Gold (NYSE:ACT) - August 16 at 3:18 PM logoIcahn Adds Allergan Stake; Sells Enzon, Seventy Seven Holdings - Bloomberg (NYSE:ACT) - August 16 at 11:54 AM logoIcahn makes new bet on Allergan in Q2 -filing (NYSE:ACT) - August 16 at 11:54 AM logoIcahn Bets Big on Allergan; Trims PayPal Stake (NYSE:ACT) - August 16 at 11:54 AM logoWill Allergan (AGN) Stock Be Helped as Icahn Makes New Bet on Shares? (NYSE:ACT) - August 16 at 11:54 AM logoIcahn makes new bet on Allergan, cuts Hertz in Q2 - filing (NYSE:ACT) - August 15 at 8:50 PM logoWhy Allergan is Fine Without Large M&A (NYSE:ACT) - August 15 at 3:20 PM logoWhat Allergan's Acquisition Could Mean For Its Future - Seeking Alpha (NYSE:ACT) - August 14 at 8:05 AM
News IconLawsuit on IRS Inversion Rules May Be 'Fascinating' Battle - Bloomberg BNA (NYSE:ACT) - August 12 at 3:18 PM logoAllergan to Acquire Eye Care Company ForSight VISION5 Adding ... - PR Newswire (press release) (NYSE:ACT) - August 11 at 3:20 PM logoAllergan to Acquire Eye Care Company ForSight VISION5 Adding Peri-Ocular Ring Technology to Company's … (NYSE:ACT) - August 11 at 12:32 PM logoAllergan agrees to buy private biotech ForSight VISION5 for $95 mln (NYSE:ACT) - August 11 at 12:32 PM logoAllergan Bought Itself an Exciting Opportunity in ForSight (NYSE:ACT) - August 11 at 12:32 PM logoCardiome Announces XYDALBA™ Single Dose Infusion Approval by European Medicines Agency - PR Newswire (press release) (NYSE:ACT) - August 10 at 3:39 PM logoAllergan Narrowly Beats Earnings, Thanks to Sales Surge (NYSE:ACT) - August 9 at 3:36 PM
News IconBusiness Groups Sue to Thwart U.S. Crackdown on Corporate Inversions (NYSE:ACT) - August 9 at 12:02 PM logoALLERGAN PLC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NYSE:ACT) - August 9 at 12:02 PM
News IconParalyzing toxins in Botox 'DO spread to other parts of your body - Daily Mail (NYSE:ACT) - August 8 at 8:45 PM
News IconStock Indexes Close Slightly Lower - DTN The Progressive Farmer (registration) (blog) (NYSE:ACT) - August 8 at 8:45 PM logoWhy Allergan plc Ordinary Shares (AGN), AMN Healthcare Services, Inc. (AHS) and Bristol-Myers Squibb Co (BMY) Are 3 of Today’s Worst Stocks (NYSE:ACT) - August 8 at 5:03 PM logoUS STOCKS-Wall Street steps back from record highs (NYSE:ACT) - August 8 at 3:18 PM
News IconBusiness Groups Sue to Thwart US Crackdown on Corporate Inversions - Insurance Journal (NYSE:ACT) - August 8 at 8:05 AM logoAllergan reports 2Q loss (NYSE:ACT) - August 8 at 8:05 AM logoAllergan revenue disappoints as Alzheimer drug loses exclusivity (NYSE:ACT) - August 8 at 8:05 AM logoWhy Allergan Earnings Aren’t Telling the Whole Story (NYSE:ACT) - August 8 at 8:05 AM logoEarnings Scheduled For August 8, 2016 (NYSE:ACT) - August 8 at 5:15 AM logoHere's Why Allergan's Earnings Report Could Be Lackluster (NYSE:ACT) - August 7 at 3:18 PM


Allergan plc (NYSE:ACT) Chart for Monday, August, 29, 2016

Last Updated on 8/29/2016 by Staff